Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study.

Wu HH, Wang PH, Chen YJ, Chao WT

Open source

DOI
10.1016/j.jfma.2024.08.014
Published
2025 Aug
Container
Journal of the Formosan Medical Association = Taiwan yi zhi
Publisher
Not recorded
Open access
no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jfma.2024.08.014,
  title = {Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study.},
  author = {Wu HH and Wang PH and Chen YJ and Chao WT},
  year = {2025},
  journal = {Journal of the Formosan Medical Association = Taiwan yi zhi},
  doi = {10.1016/j.jfma.2024.08.014},
  url = {https://doi.org/10.1016/j.jfma.2024.08.014}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study.
AU  - Wu HH
AU  - Wang PH
AU  - Chen YJ
AU  - Chao WT
PY  - 2025
JO  - Journal of the Formosan Medical Association = Taiwan yi zhi
DO  - 10.1016/j.jfma.2024.08.014
UR  - https://doi.org/10.1016/j.jfma.2024.08.014
ER  - 

APA

HH, W., PH, W., YJ, C., & WT, C. (2025). Efficacy and safety of oxaliplatin-based hyperthermic intraperitoneal chemotherapy with secondary cytoreduction for platinum resistant recurrent ovarian cancer: A single-center retrospective cohort study.. Journal of the Formosan Medical Association = Taiwan yi zhi. https://doi.org/10.1016/j.jfma.2024.08.014

Source records